Ilenia Calcaterra: Clinical Relevance of Persistent Pain in Emicizumab-Treated Haemophilia A
Ilenia Calcaterra, Consultant Physician in Internal Medicine and Assistant Professor at the University of Naples Federico II, shared a post on LinkedIn:
“Honored to have presented our work during the free paper session at the WFH 2026 World Congress in Kuala Lumpur.
In this study, we explored the multidimensional pain experience of adults with severe haemophilia
A receiving Emicizumab prophylaxis using the Multidimensional Haemophilia Pain Questionnaire (MHPQ).
Our findings highlight an important clinical message: even in the era of highly effective bleed prevention, pain remains prevalent and functionally relevant, suggesting that haemophilia-related pain is not exclusively bleeding-driven and deserves structured, multidimensional assessment in routine care.
Grateful for the opportunity to share our data, for the stimulating scientific discussion, and for the chance to contribute to ongoing research aimed at improving the lives of people with haemophilia.”
Other posts featuring Ilenia Calcaterra on Hemostasis Today.
-
Sep 11, 2026, 13:10Tessa Youngner: New Free E-Course Introduces Comprehensive SCD Care
-
Sep 11, 2026, 12:55Identifying Key Research Priorities for VTE and Stroke – International Journal of Stroke
-
Sep 11, 2026, 12:43Helping Hematology Employers Reach Qualified Job Seekers – ASH
-
Sep 11, 2026, 12:22The First New Treatment for Essential Thrombocythemia in Nearly 30 Years
-
Sep 11, 2026, 12:20When Thrombosis Affects the Kidneys – World Thrombosis Day
-
Sep 11, 2026, 11:24Haroun Gajraj: Polidocanol or STS – Choosing the Right Sclerosant
-
Sep 11, 2026, 10:53A Patient-Centred Approach to Haemophilia B Care – EAHAD
-
Sep 11, 2026, 09:51Alfredo Lozada: Pelacarsen Lowers Lp(a), But Does It Lower CV Risk?
-
Sep 11, 2026, 09:35Yasir Khan: Travel Related Blood Clots – What Are the Chances?